AGP Picks
View all

Regeneration Biomedical reports positive Phase 1 Alzheimer’s stem cell data

Nov. 18, 2026
Regeneration Biomedical reports positive Phase 1 Alzheimer’s stem cell data
By AI, Created 15:15 UTC, Nov 18, 2026, AGP -

Regeneration Biomedical says its first-in-human Alzheimer’s trial of direct-to-brain stem cells showed favorable safety and biomarker improvements through 52 weeks in six patients. The company also says the FDA granted Fast Track designation and a Phase 2 study could start as early as December 2026.

Why it matters: - Regeneration Biomedical’s early data could help advance a new Alzheimer’s approach that bypasses the blood-brain barrier and delivers cells directly into the brain’s ventricular system. - The study also adds momentum for the company’s planned Phase 2 trial and broader regenerative medicine pipeline. - The FDA granted Fast Track designation for RB-ADSC, which can speed development for therapies targeting serious conditions with unmet medical needs.

What happened: - Regeneration Biomedical announced first-in-human Phase 1 results for RB-ADSC, a Wnt-activated autologous adipose-derived stem cell therapy for Alzheimer’s disease. - The findings are being presented at the Clinical Trials on Alzheimer’s Disease 2026 conference in Boston. - The Phase 1 trial enrolled six patients with mild-to-moderate Alzheimer’s disease. - Each patient received a single intracerebroventricular administration directly into the brain’s ventricular system. - The company says a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial could begin as early as December 2026.

The details: - RB-ADSC uses autologous adipose-derived stem cells expanded under proprietary conditions involving activation of the Wnt signaling pathway. - Intracerebroventricular delivery is designed to introduce cells directly into cerebrospinal fluid and bypass the blood-brain barrier. - The study is the first clinical evaluation of this specific Wnt-activated autologous stem cell platform delivered intracerebroventricularly for Alzheimer’s disease. - The trial showed a favorable safety profile through 52 weeks, with no serious adverse events attributed to the therapy. - All three longitudinal CSF Alzheimer’s biomarkers studied showed statistically significant changes from baseline at 12, 28 and 52 weeks. - At 52 weeks, the reported biomarker changes remained statistically significant for Aβ42, with p < 0.001, phosphorylated tau, with p = 0.001, and total tau, with p = 0.007. - Additional analyses showed statistically significant reductions in histone H2B and neurofilament light polypeptide at 12 weeks. - Exploratory cognitive assessments improved on one or more measures in about 80% of participants. - Reductions in amyloid PET burden were seen in a subset of patients. - The study was small and uncontrolled, so it was not designed to prove clinical efficacy. - Regeneration Biomedical says the persistence of biomarker changes through one year supports further Phase 2 study. - The FDA granted Fast Track designation for RB-ADSC for Alzheimer’s disease, which can allow more frequent agency interactions and possible rolling review of a future Biologics License Application. - Phase 2 is expected to evaluate safety and efficacy through cognitive assessments and Alzheimer’s biomarkers. - The Phase 2 protocol will include repeated intracerebroventricular administration to test continued treatment effects. - Regeneration Biomedical is also seeking funding to expand the platform into amyotrophic lateral sclerosis, or ALS.

Between the lines: - The headline safety finding matters because direct-to-brain delivery raises obvious risk concerns, and the absence of serious therapy-related adverse events is an important early signal. - The biomarker changes are encouraging, but the tiny sample size and lack of a control arm mean the results are hypothesis-generating, not proof of benefit. - The company is positioning the platform as both a disease-targeting therapy and a potential way to stimulate the brain’s own repair pathways, but those regenerative mechanisms remain investigational. - Founder Christopher Duma said the trial marks an important milestone and called the results an encouraging foundation for larger testing.

What’s next: - Regeneration Biomedical is preparing the Phase 2 study and says it could start as early as December 2026, subject to operational readiness and site activation. - The company will look to confirm the Phase 1 biomarker and cognitive findings in a larger, rigorously controlled trial. - Regeneration Biomedical is seeking strategic partners and funding to move the platform toward ALS development. - The company says FDA Fast Track designation and Phase 2 planning are key regulatory steps toward further development.

The bottom line: - Regeneration Biomedical has early safety and biomarker data that support continued study of its direct-to-brain stem cell therapy for Alzheimer’s, but larger controlled trials will need to show whether those signals translate into real clinical benefit.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Boston Technology Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Boston Technology Review

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.